In this article, we will discuss the 10 Cheap NASDAQ Stocks to Buy Right Now.

On April 28, Gabelli’s John Belton joined CNBC’s ‘Closing Bell Overtime’ to analyze the market environment heading into earnings season. Belton explored the recent surge in Mag 7 type stocks, suggesting that the late March low and a potential ceasefire in Iran may have coincided with the introduction of the mythos model, which acted as an accelerant for the sector. When questioned about whether AI market winners are easily defined or if there is indiscriminate buying, he acknowledged the complexity of the situation. He highlighted that beyond the mythos catalyst, he is particularly excited by the revenue figures from Anthropic and OpenAI, which have collectively reached an estimated $70 billion in annualized run-rate revenue, more than doubling since the beginning of the year. He argued that this development effectively addresses the earlier debate regarding whether companies were spending heavily on infrastructure without achieving monetization, asserting that the shift toward direct AI monetization is a crucial development.

Regarding investor expectations for CapEx plans, Belton observed that the first-quarter earnings cycle historically does not see major changes to full-year outlooks, so he expects plans to be reiterated or only slightly increased. He noted that the more critical issue for investors is understanding where that capital is being allocated, specifically, whether it is directed toward visible ROI use cases or more speculative research and development. He identified cloud revenue acceleration as the primary theme of the upcoming earnings season.

Our Methodology

We used screeners to identify NASDAQ stocks that are trading below a forward P/E of 15, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2025.

Note: All data was sourced on May 22. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Cheap NASDAQ Stocks to Buy Right Now

10. JD.com Inc. (NASDAQ:JD)

Number of Hedge Fund Holders: 51

JD.com Inc. (NASDAQ:JD) is one of the cheap NASDAQ stocks to buy right now. On May 12, JD.com announced its financial results for Q1 2026, reporting net revenues of RMB315.7 billion, a 4.9% increase year-over-year. Net income attributable to ordinary shareholders was RMB5.1 billion, while non-GAAP net income reached RMB7.4 billion.

JD Retail showed strong performance with an operating margin of 5.6%, reaching record profitability levels. The company also continued its share repurchase program, buying back approximately 1.6% of its outstanding shares for $631 million during the quarter.

The company highlighted ongoing operational progress across its segments, including JD Logistics’ technological advancements and the international expansion of its Joybuy retail service in Europe. Additionally, boards of several subsidiaries approved restricted share unit grants to Richard Qiangdong Liu to support long-term value creation.

JD.com Inc. (NASDAQ:JD) is an internet retail and supply chain-based technology company. It also acts as a service provider and has three segments: JD Retail, JD Logistics, and New Businesses.

9. ​Kimberly-Clark Corporation (NASDAQ:KMB)

Number of Hedge Fund Holders: 56

​Kimberly-Clark Corporation (NASDAQ:KMB) is one of the cheap NASDAQ stocks to buy right now. On April 28, Kimberly-Clark reported solid Q1 2026 results, delivering $4.2 billion in net sales, a 2.7% increase year-over-year. Organic sales grew by 2.5%, fueled by consumer-inspired innovation and volume-plus-mix growth, even as the company navigated macroeconomic uncertainties and ongoing portfolio transitions.

The company achieved an adjusted operating profit of $732 million, a 3.7% increase compared to the prior year, supported by significant productivity savings and lower overhead costs. While adjusted EPS from continuing operations saw a slight decline of 1.2% due to tax factors, adjusted EPS attributable to the total corporation rose by 2.1%.

Looking ahead, ​Kimberly-Clark Corporation (NASDAQ:KMB) reaffirmed its 2026 outlook, expecting organic sales growth to remain consistent with or ahead of category averages. Management continues to focus on long-term value creation, including preparations for the upcoming Kenvue acquisition and continued investment in commercial activations and sustainable productivity.

​Kimberly-Clark Corporation (NASDAQ:KMB) is a global company focused on products and solutions for personal care. It operates through two segments: North America and International Personal Care.

8. Roper Technologies, Inc. (NASDAQ:ROP)

Number of Hedge Fund Holders: 61

Roper Technologies, Inc. (NASDAQ:ROP) is one of the cheap NASDAQ stocks to buy right now. On April 23, Roper Technologies reported a strong Q1 2026, with revenue increasing 11% to $2.10 billion, driven by 6% organic growth and contributions from acquisitions. Adjusted net earnings rose 4% to $539 million, while adjusted diluted EPS grew 8% to $5.16.

The company demonstrated significant capital deployment efficiency, repurchasing 4.3 million shares for $1.5 billion during the quarter. Furthermore, the board authorized an additional $3 billion for share repurchases, highlighting a focus on compounding long-term free cash flow per share.

Following these results, Roper Technologies Inc. (NASDAQ:ROP) raised its full-year 2026 adjusted diluted EPS guidance to a range of $21.80 – $22.05. Management attributed this positive outlook to resilient demand for their mission-critical solutions and the company’s accelerated speed in delivering AI-integrated products to vertical markets.

Roper Technologies Inc. (NASDAQ:ROP) operates as a diversified technology company, focused on vertical software and technology-enabled products across niche markets. Its business is organized into three segments: Application Software, Network Software, and Technology Enabled Products.

7. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 70

Amgen Inc. (NASDAQ:AMGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Amgen announced the retirement of its Executive Vice President and Chief Financial Officer, Peter Griffith, who has held the role since 2020. During his tenure, Griffith was instrumental in strengthening the company’s financial position, supporting capital allocation, and driving its long-term growth strategy.

Thomas Dittrich has been named as Griffith’s successor. He will return to Amgen on July 1 as Executive Vice President, transitioning into the Chief Financial Officer role on September 1. Dittrich brings over 30 years of international experience in the biopharmaceutical and healthcare sectors, including previous CFO roles at Galderma, Shire, and Sulzer.

To ensure a seamless leadership transition, Griffith will remain with the company through January 2027. Dittrich will oversee all aspects of the firm’s financial operations, continuing Amgen’s focus on delivering long-term growth and patient-centered care.

Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.

6. Gilead Sciences Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 71

Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ proprietary antibody-drug conjugate/ADC platform and promising clinical assets, including the lead candidate TUB-040, which is currently being evaluated for platinum-resistant ovarian and non-small cell lung cancers.

As part of the acquisition, the Tubulis team will remain in Munich to establish “The Tubulis ADC Innovation Center.” This new hub will serve as the company’s center for ongoing ADC research, manufacturing, and clinical development, allowing Gilead to use Tubulis’ expertise in creating highly selective, next-generation therapies designed to maximize anti-tumor activity while limiting side effects.

The acquisition deepens Gilead Sciences Inc.’s (NASDAQ:GILD) commitment to advancing transformative cancer treatments through targeted technologies. By combining Gilead’s existing oncology infrastructure with Tubulis’ innovative ADC platform, the company aims to address significant gaps in care for patients with challenging forms of solid tumors, further cementing its position as a leader in oncology innovation.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

Click to continue reading and see the 5 Cheap NASDAQ Stocks to Buy Right Now.

Disclosure: None. None. Follow Insider Monkey on Google News.